Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in recently diagnosed type 2 diabetes mellitus
NCT00832390Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2007
- Primary completion
- Jul 2008
01
Overview
Phase 4, single-arm trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoint: Glycated Hemoglobin at 24 weeks. Started Feb 2007; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00832390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00832390.